



Glossary

A glossary of terms is provided for readers who are not experts of the inositol lipid field.

myo-Inositol: This is one of nine possible stereoisomers of inositol which is a cyclohexanehexol. *Myo*-inositol is the most commonly occurring stereoisomer in nature, therefore, the IUPAC-approved abbreviation “Ins” refers to *myo*-inositol (Nomenclature Committee of the International Union of Biochemistry, 1989, <http://www.chem.qmul.ac.uk/iupac/cyclitol/myo.html>). The conformation of *myo*-inositol is the so-called “chair” conformation with five equatorial and one axial hydroxyl groups. This conformation, and the numbering of the hydroxyls have been best visualized by Agranoff (1978) who compared the ring to a turtle and the hydroxyls to the appendages. Here, the numbering starts with the right front flipper going counterclockwise. The head of the turtle then corresponds to the axial hydroxyl at the 2nd position. It is notable that *myo*-inositol has an axis of symmetry going through the 2nd and 5th carbons. The numbering used refers to the D-enantiomers but it is important to remember that because of this symmetry D-Ins1*P* is the same as L-Ins3*P* and, therefore, isomers (such as Ins1*P* and Ins3*P*) that are enantiomeric twins cannot be separated with conventional HPLC methods.




Agranoff's turtle



myo-inositol

Phosphatidylinositol: This is the base molecule for all phosphoinositides. The recommended abbreviation is PtdIns (<http://www.chem.qmul.ac.uk/iupac/misc/phos2t8.html#t4>) but the early literature often uses “PI” as the abbreviation. This short form is still in use in the context of kinases that phosphorylate PtdIns or its phosphorylated derivatives, such as in PI 3-kinases or PI 4-kinases. PtdIns consists of a diacylglycerol backbone in which the 1- and 2-positions of the glycerol are most often esterified with a stearyl- and arachidonyl- fatty acid chains, respectively, and the *myo*-inositol ring is linked to the 3rd- position of the glycerol via a phosphodiester bond formed with the 1st hydroxyl of inositol. PtdIns can be phosphorylated in all but the 2nd and 6th positions of the inositol ring, giving rise to the seven known phosphoinositides.



Polyphosphoinositides: This refers to any of the further phosphorylated PtdIns regardless of the number and positions of the phosphate groups. Sometimes they are abbreviated as PPIs but mostly in the 80's literature but this is still the recommended abbreviation (see in [Michell et al. 2005](#)).

Phosphoinositides: This is a term often used to designate collectively PtdIns and all of its phosphorylated derivatives regardless of their isomerism. “PI” is the abbreviation used lately for phosphoinositides but it often causes confusion so it should be avoided. There is no consensus abbreviation for this term that includes both PtdIns and the PPIs. The individual forms of PPIs are abbreviated specifying the

positions phosphorylated on the inositol ring. For example, phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5) P_2] is a double phosphorylated PtdIns with positions 4- and 5- phosphorylated.

It is worth pointing out here a few rules about the terminology: the numbers on the inositol ring are not “primed”, since there is no other ring in the structure that would require the use of “prime” to discriminate the rings (as opposed to multiring structures such as the nucleosides). The number of phosphates are indicated by the prefixes “bis-” (latin for twice) “tris-” (greek for three times) to indicate that these molecules contain the indicated number of phosphates but all placed individually at various positions. (contrast this with ATP which is a “triphosphate” with the phosphates linked to one another). There are no higher numbers than trisphosphates in phosphoinositides but there are in the soluble inositol phosphates, for which the numbers continue as “tetrakis-”, “pentakis-” and “hexakis-” ‘kis’ being a greek prefix for –times. In the abbreviations it is recommended to italicise the “*P*” if it designates a phosphomonoester (see Michell et al. (2005) in the list below for more details on nomenclature recommendations).

Old literature used terms such as “DPI” and “TPI” for diphosphoinositide and triphosphoinositide, respectively. These correspond to mono- and bis-phosphorylated PtdIns from a time when the exact configurations of the phosphates were not known.

Phosphoinositide kinases: Phosphoinositide kinases add a phosphate to a specific position onto the inositol ring of phosphoinositides using ATP. The kinases are named after the position they phosphorylate and hence we distinguish 3-, 4- and 5-kinases (no primes!!). There is an inherent inconsistency about the abbreviations used to designate these enzymes. For example, the term “PI 3-kinase” is used to refer to any of the 3-kinases, regardless of the substrates they phosphorylate. Since there are PI 3-kinases that can only phosphorylate PtdIns (and not further phosphorylated forms) (the Class III PI 3-kinases) they are also named PtdIns 3-kinases. However, the Class I PI 3-kinases that phosphorylate PtdIns(4,5) P_2 are rarely called PtdIns(4,5) P_2 3-kinases and in most articles unspecified “PI 3-kinase” refers to the Class I enzymes. In contrast, PI 4-kinases can only phosphorylate PtdIns (and not further phosphorylated forms) in which case it would be more correct to call them PtdIns 4-kinases. However, because of historical reasons, these inconsistencies are tolerated even if they defy logic based on current knowledge. The list of the various forms and classes of PI kinases are summarized in the respective chapters.

Phosphoinositide phosphatases: Phosphoinositide phosphatases remove one or more phosphates from PPIs. They can be specific to the position of the phosphate they remove and the substrate they can use. Some will dephosphorylate only PPIs while others can also use the water-soluble inositol phosphates as substrates. Phosphatases are usually named after the position of phosphate they attack such as 5-phosphatases or 3-phosphatases. Some PI phosphatases are not position specific, such as the monophosphatases (see Chapters 7 and 8 in Volume I for more details).

Phospholipase C: These enzymes (PLCs) hydrolyze PtdIns (or PPIs) by cleaving the phosphodiester group such that they leave diacylglycerol behind and release the

inositol headgroup, which carries the phosphate still attached at the 1-position (or other phosphates if the substrate is any of the PPIs). To discriminate from other PLCs that use other phospholipids as substrate (such as PC-PLC), PLCs that hydrolyze phosphoinositides are called PI-PLCs. This, however, also causes some confusion, since mammalian PI-PLCs are believed to hydrolyze primarily PtdIns(4,5) P_2 *in vivo* (although they can also hydrolyze PtdIns and PtdIns4*P* *in vitro*). However, there are bacterial PLC enzymes that will use either PtdIns or phosphatidylinositol glycan (GPI) linkages but cannot hydrolyze polyphosphoinositides. The literature that deals with the bacterial enzymes uses the term PI-PLC to emphasize that the bacterial enzymes are specific for PtdIns or GPI. So the term “PI-PLC” means two different enzyme groups depending on whether used in mammalian or prokaryotic studies. However, in most cases PLC without any designation refers to the mammalian phosphoinositide-specific PLCs.

Inositol 1,4,5-trisphosphate: Ins(1,4,5) P_3 is the water soluble molecule liberated after PLC-mediated hydrolysis of PtdIns(4,5) P_2 . This molecule has a receptor located in the ER membrane that also is a Ca^{2+} channel and which is gated by Ins(1,4,5) P_3 binding. Ins(1,4,5) P_3 is a bona fide second messenger liberated upon stimulation of cell surface receptors coupled to PLC activation.

PH domain: PH domains (for pleckstrin homology domains) are protein modules of roughly 150 amino acid length that were first recognized in pleckstrin (Tyers et al. 1988). These were the first protein modules that were shown to bind PPIs. Many PH domains can recognize and bind phosphoinositides with variable specificities earning these domains the reputation of being PPI binding modules. Although several PH domains can, indeed, recognize PIs with high affinity and specificity, many PH domains show promiscuous PPI recognition and many do not bind PIs at all. Moreover, PH domains also recognize proteins and often bind proteins and lipids simultaneously (Lemmon 2004).

FYVE domain: This was the second protein module identified with specific PPI recognition, namely to recognize PtdIns3*P* (Burd and Emr 1998). Its name originated from the four molecules (three from baker’s yeast) in which this module was first described (Fab1, YOTB, Vac1 and EEA1). FYVE domains use two Zn^{2+} ions to stabilize their structure and they are also called FYVE zinc fingers. They show structural similarities to the C1 domains that recognize diacylglycerol (Misra and Hurley 1999; Kutateladze et al. 1999).

PX domain: Phox-homology domains were also recognized as capable of binding PtdIns3*P*. They were initially found in sorting nexins (Ponting 1996) and NADPH oxidase subunits (Bravo et al. 2001; Ellson et al. 2001; Kanai et al. 2001), but they are present in a large variety of signaling molecules. PX domains can also bind other phospholipids, such as PtdOH and PtdIns(3,4) P_2 , and they also interact with proteins (Vollert and Uetz 2004).

Phosphoinositide binding protein domains: In addition to the above defined protein modules, several other modular protein domains have been identified as phosphoinositide effectors (Lemmon 2008). Because of their increasing number they will not be listed here but can be found in the individual Chapters.

References

- Agranoff BW (1978) *Trends Biochem Sci* 3(12):N283–N285
- Bravo J, Karathanassis D, Pacold CM, Pacold ME, Ellson CD, Anderson KE, Butler PJG, Lavenir I, Perisic O, Hawkins PT, Stephens L, Williams RL (2001) *Mol Cell* 8:829–839
- Burd CG, Emr SD (1998) *Mol Cell* 2:157–162
- Ellson CD, Gobert-Gosse S, Anderson KE, Davidson K, Erdjument-Bromage H, Tempst P, Thuring JW, Cooper MA, Lim ZY, Holmes AB, Gaffney PRJ, Coadwell J, Chilvers ER, Hawkins PT, Stephens LR (2001) *Nat Cell Biol* 3:679–682
- Kanai F, Liu H, Field SJ, Akbary H, Matsuo T, Brown GE, Cantley LC, Yaffe MB (2001) *Nat Cell Biol* 3:675–678
- Kutateladze TG, Ogburn KD, Watson WT, deBeer T, Emr SD, Burd CG, Overduin M (1999) *Mol Cell* 3:805–811
- Lemmon MA (2004) *Biochem Soc Trans* 32:707–711
- Lemmon MA (2008) *Nat Rev Mol Cell Biol* 9(2):99–111
- Michell RH, Heath VL, Lemmon MA, Dove SK (2005) *Trends Biochem Sci* 31(1):52–63
- Misra S, Hurley JH (1999) *Cell* 97:657–666
- Ponting, CP (1996) *Prot Sci* 5:2353–2357
- Tyers M, Rachubinski RA, Stewart MI, Varrichio AM, Shorr RG, Haslam RJ, Harley CB (1988) *Nature* 333(6172):470–473
- Vollert CS, Uetz P (2004) *Mol Cell Proteomics* 3(11):1053–1064

Index

A

- A1 adenosine receptors, 127
Abl, 221
Actin cytoskeleton, 99, 104, 217, 226, 227, 238
Actin-regulatory protein, 68, 227
Acute lymphocytic leukemia, 226, 291
Acute myeloid leukemia, 226, 291
ADAMs, 241
 α -Adaptin, 39
Adenocarcinoma cells, 235, 243, 292, 294, 296, 306
Adenylyl cyclase, 78, 79, 201, 202
3T3 L1 adipocytes, 228, 234
 β -Adrenergic receptor, 79, 135, 198, 201, 202
Aedes aegypti, 75
age-1, 100
Airway hyper-responsiveness (AHR), 141, 189, 193
Akt, 100, 101, 103, 104, 134, 136, 139, 149, 196, 199, 202, 247, 251, 296
Akt1, 104, 130, 196, 199
Akt2, 104, 196
Akt3, 104
Akt activation, 99, 100, 131, 222, 223, 228–231, 241, 242, 247, 248, 250, 284, 297, 302
Alpha-actinin, 36
Alzheimer, 70, 302
Amoeboid migration, 99, 138
Amphiphysin 1, 231, 232
Amphiphysin 2, 231
Amyotrophic lateral sclerosis, 255
Angiotensin II, 11, 69, 139
ANTH domain, 135
Anti-nuclear autoantibodies, 142
AP-1, 13
AP-2, 38, 39, 41–44, 203, 231, 236, 237, 240
AP-3, 13, 14
AP-4, 39
AP180, 38, 43
Apoptosis signal-regulating kinase 1 (ASK1), 302
APPL1, 237–239
Arabidopsis thaliana, 252
Arf1, 13–15, 17
Arf6, 37
Arp2/3 complex, 68
ArPIKfyve protein, 254
AS160, 196
AS1949490, 230
ASH domain (ASPM/SPD2/hydin), 218, 236, 240
Aspergillus niger, 307
Asthma, 140, 141, 189, 193, 194, 225, 248
Astrocyte, 13, 78, 290
Ataxia, 74, 116, 232, 235, 247, 293, 295, 301
Ataxia telangiectasia-related (ATR), 116
Atg6, 130
Atg14L, 130
ATM (ataxia telangiectasia mutated), 8, 116
Atypical G-protein transglutaminase II, 69
Autoimmune disease, 126, 136, 138, 141–143, 192, 193, 224, 289, 297
Autoinhibition, 75, 81
Autophagosome, 312, 314, 315
Autophagy, 116, 130, 255, 306, 314, 315; *see also* PI3K complexes I and II
Autosomal-dominant cancers, 147, 255, 283, 289, 313
Auxilin, 102
Azospermia, 308, 313

B

- B lymphocytes, 136, 185, 189, 191, 192, 222
BAD, 100, 134
BAF complex, 48
BaF3 cell, 146

- Bannayan-Zonana syndrome, 183, 189, 301
 Basal body, 235
 BCR (B cell receptor), 126, 128, 137, 191, 222, 290
 BCR/ABL (break point cluster region/Abelson kinase fusion protein), 126, 227
 Beclin-1, 130
 Bergmann glia, 13
 Bilateral congenital cataracts, 236
 Bi-polar disorder, 233
 Bladder cancer, 243
 Breast cancer, 102, 144, 248, 250, 251
 Brefeldin A, 9, 14
 Bronchoalveolar lavage (BAL), 189
 Bruton's tyrosine kinase (Btk), 135, 140, 188, 226
 Burkitt lymphoma, 243
- C**
- C2 domain, 37, 65, 68, 128, 246, 284, 286, 287, 298
 C3 botulinum toxin, 78
 C5a, 128, 187
 Ca²⁺ channel, 140
 Ca²⁺ signaling, 80
 Ca²⁺/calmodulin kinase II, 239
 CAAX motifs, 218, 234, 235, 239, 240
Caenorhabditis elegans, 4, 71, 75, 76, 100, 129, 232, 233, 307, 314, 315, 318
 Calcineurin, 43, 232
 Calpain, 38
 cAMP, *see* Cyclic AMP
 Capping protein/CapZ, 33
 Cardiomyocyte, 101, 127, 139, 140, 198, 199, 201–203, 290, 291
 Cardiotoxicity, 199
 Caspase-3, 302
 Caspase 9, 134
 β -catenin, 10
 CBRIII motif, 287
 CD2-associated protein, 228
 CD4⁺ T cells, 143, 190, 193, 305, 316
 CD8⁺ T cells, 136, 190, 194
 CD19, 126
 CD40, 191
 CD62L, 191
 CD63, 13
 CD81, 10
 Cdc42 (cell division cycle 42), 35, 135, 136, 237, 240, 287
 Cdc42/N-WASP, 35
 Cdc42-GAP, 35, 135, 136, 240, 287
 Cell death, 71, 150, 199, 225, 231, 247, 293, 302, 316
 Cell motility, 70, 99, 251, 298
 β -Cells, 16, 194, 195, 294
 Cell senescence, 297, 300, 301
 Cell wall abnormalities, 252
 Cellular cilia, 235
 Ceramide transfer protein (CERT), 16
 Cerebellum, 71, 245, 250, 290
 Charcot-Marie-Tooth (CMT) disorder, 112, 255, 313
 Chemotaxis, 73, 74, 143, 187, 189, 190, 192, 222, 245, 249, 293, 298, 305
 Chloride channel, 246
 Chromaffin cells, 37
 Chromosome 10q, 239
 Chromosome 10q23, 101
 Chromosome 22q12, 241
 Chromosome 3p22, 70
 Chromosome 17p13.3, 243
 Chronic lymphocytic leukaemia, 243
 Chronic myelogenous leukaemia (CML), 126, 151, 222, 227
 Chronic obstructive pulmonary disease (COPD), 141, 194
 Chylous ascites, 101
 Ciliopathy syndrome, 220, 235
 c-kit receptor, 141
 Clathrin-coated vesicles, 39, 41, 43, 227, 232, 238
 Clathrin-mediated endocytosis, 38, 39, 42, 43, 116, 232, 233
 CMT4J patients, 255
 Coated pits, 39, 43, 203, 228, 231, 232, 234, 237
 Coatmer protein complex I (COP-I), 253
 Coatmer protein complex II (COP-II), 253
 Cochlea, 233
 Cofilin, 33, 68
 Coiled-coil domain, 71, 72, 307, 314
 Compartmentalization, 202
 Congenital cataracts, 236
 COP-I-vesicle, *see* Coatmer protein complex I
 COP-II vesicle, *see* Coatmer protein complex II
 COS-7 cells, 14, 16, 80
 Cowden disease, 283, 284, 286, 288, 289, 301
 Craniofacial/limb abnormalities, 242
 Cubulin, 239
 Cul3-SPOP (cullin 3-speckle-type POZ domain protein), 47, 48
 Cutaneous melanoma, 243

CX₅R catalytic motif, 216, 282, 284
 Cyclic AMP (cAMP), 78, 79, 101, 140, 201, 202
 Cytochrome c, 302, 303

D

DAAX (death domain-associated protein), 288
 daf16, 100
Danio rerio, 233, 315, 318
 DAPI2, 226
 DAPI60 (dynamin-associated protein 160), 231
 Dbl, 235
 dbl-homology (DH), 249
 Degenerative neuropathy, 255
 Degranulation, 141, 142, 188, 189, 225
 Demyelinating neuropathy, 313
 Dendritic spines, 293
 Dent-2 disease, 236–240
 DEP domain, 249
 Desmin, 316
 DHR-1 domain, 135, 136
 Diabetic nephropathy, 228
 Diacylglycerol (DAG), 16, 45, 62, 96
 Diacylglycerol kinase, 45
 Diacylglycerol-activated serine/threonine protein kinase (PKC), 96
Dictyostelium discoideum, 67, 99, 113, 138, 287, 298
 Disc-large1 (Dlg1), 314
 DJ-1, 302, 303
 DNA repair, 47, 289, 307
 DNA-dependent protein kinase (DNA-PK_{cs}), 116, 117, 130
 DOCK2, 136, 138, 191
 Dok 1, 221
 Dok 2, 221, 223
 Dominant-negative, 199, 230
 Dorsal ruffles, 33
 Down's syndrome, 233
 Dpm1 (Dolichol phosphate mannosyltransferase), 253
Drosophila melanogaster, 113, 232, 233, 252, 305, 310, 315, 318
 Drug target, 143
 Dynamin-2, 38, 43
 Dynamin oligomer, 38, 43, 129, 231; *see also* Clathrin-coated vesicles and Clathrin-mediated endocytosis

E

E-cadherin, 37, 40, 41
 EEA1, 14, 129, 311; *see also* FYVE domain
 EF-hand, 64, 80

EGFR, 10, 13, 36, 44, 76, 116, 144, 147, 300
 EGFR degradation, 230, 244, 315, 316
 Embryonic development, 134, 217, 234, 235, 242, 283, 287
 Embryonic lethality, 70, 76, 101, 150, 220, 221, 235, 243, 289
 Endocytic recycling compartment, 15, 36
 Endometrioid carcinoma, 296
 Endophilin 1, 232
Entamoeba histolytica, 307
 ENTH domain, 135
 ENTH/ANTH domain, 135
 ENU mutagenesis screen, 233
 Eosinophils, 185, 188, 189, 193
 Eotaxin, 189
 Epac, 79
 Epinephrine, 201
 Eps15, 231
 Epsin, 38, 43
 ERK, 78, 97, 103
 Erlotinib, 151
 Erythroleukemia, 45, 227
 Erythropoiesis, 76
 Erythropoietin (Epo), 227
 Estrogen receptor, 102, 241, 248
 Eukaryotic elongation factor 1A, 13
 Everolimus, 120, 148
 Excised patch recording, 19, 27, 83
 Exo70, 37
 Exocyst complex, 36, 37, 316
 Extracellular matrix, 299

F

Fab1/PIKfyve, 135, 254; *see also* FYVE domain
 Fab1p, 26, 27
 FAK, 38, 286
 FAPP1, 12, 14, 16
 FcγR-mediated phagocytosis, 224, 225, 234, 305
 FERM domain, 135
 Fibroblast growth factor (FGF), 17, 74
 Fibronectin, 37
 Fig4, 254, 255
 Filamin, 227
 Filopodia, 33, 314
 FK506-binding protein 12 (FKBP12), 147
 Fluorescence resonance energy transfer (FRET), 104
 FMLP (formylmethionyl leucyl phenylalanine), 97, 98, 187, 188
 Focal adhesions, 36–38
 Foxn1, 69

FoxO1, 131, 137, 196
 FOXO3a, 100, 104
Francisella tularensis, 225
 Frequentin (Frq1p), 15
 Friend murine leukemia virus, 227
 Frq1p, 16
 FYVE domain, 27, 100, 135, 196, 310, 312

G

G protein-coupled receptor (GPCR), 62, 72, 96, 127, 202, 249
 G₁/S boundary, 70
 G₂/M phase, 70
 G₂/M transition, 70
 G6P (glucose-6-phosphatase), 230
 Gastrointestinal stromal tumors, 144
 Gefitinib, 151
 Gelsolin, 33, 68
 Gemcitabine, 236, 243
 GGA protein, 13
 GGA1, 13
 GGA2, 13
 GGA3, 13, 14
 GIPC (GAIP-interacting protein, C terminus), 237–239
 GK (glucokinase), 230
 Gleevec, 144, 151
 Glioblastoma, 102, 146, 230, 234, 287, 296, 300, 304
 GLTSCR2, 286, 300
 Gluconeogenesis, 194, 196, 198, 230
 Glucose homeostasis, 196, 198, 217, 229, 230, 242
 Glucose intolerance, 196, 198
 Glucose uptake, 194–196, 228, 234, 242
 GLUT4, 196, 197, 228, 234, 242, 254
 Glutamate, 29, 247, 302
 Glycogen synthase, 100, 134, 286
 Glycogenolysis, 194
 Glycosphingolipids, 12, 17, 18
 Glycosylphosphatidylinositol (GPI), 340
 Golgi resident proteins, 16
 Golgi-ER shuttling, 253
 Golgi-localised, γ -ear-containing, Arf-binding protein (GGA), 13
 Granulocyte/macrophage colony-stimulating factor (GM-CSF), 139
 Grb2 (growth-factor-receptor-bound protein 2), 231
 Gsk3 β (glycogen synthase kinase 3 β), 11, 134, 199, 241, 254, 286
 GTPase activating proteins (GAPs), 72, 103, 135

Guanine nucleotide exchange factors (GEFs), 35, 77, 103, 112, 135, 138, 191, 248, 249
 Guanosine 3', 5'-monophosphate (GTP), 37, 65, 72, 77, 135
 G α_q , 63–65, 69, 71–74, 82

H

Hamartin, 131; *see also* TSC1
 Hamartomas, 147, 283
 HAUSP (herpes virus-associated ubiquitin-specific protease), 288
 HBV core protein, 243
 Hck, 221
 Heart failure, 140, 198, 199, 201–203, 289
 Hedgehog signalling, 17, 18
 HEK cells, 228
 HeLa cells, 230, 311, 314
 Hemidesmosomes, 36
 Hemostasis, 111, 146, 226
 Heparin, 79, 188
 Hepatitis C virus (HCV), 14
 Hepatocellular carcinoma, 10, 146, 243, 291
 Hepatocyte necrosis, 101
 Heterodimerisation, 4
 High fat diet, 220, 229, 242, 294, 295
 Histone H1, 48, 70
 Histone H3, 48
 hJumpy, 307
 Human neuropathies, 254, 255
 hVps15, 130, 314
 hVps34, 130, 314
 Hyperactivation of Akt, 102
 Hypergammaglobulinemia, 193
 Hyperglycaemia, 230
 Hyperinsulinaemia, 230
 Hyperlipidemia, 198
 Hypoglycemia, 101, 197, 294
 Hypothalamus, 234

I

IC87114, 118, 141, 150, 187, 188, 193
 IgE binding, 188
 IgE high affinity receptor (FC ϵ RI), 188
 IgE switch, 191
 IL-1 β , 69, 70
 IL-2, 142, 189, 190
 IL-4, 126, 189, 191, 224, 305
 IL-5, 189, 226
 IL-6, 69, 70, 127, 142, 223, 224, 226
 IL-8, 187
 Imatinib, 144, 151

- Immunoreceptor tyrosine-based activation motifs (ITAMs), 75, 126, 140, 188, 222, 225
- Immunoreceptor tyrosine-based inhibitory motifs (ITIMs), 222, 225
- Infertility, 71, 241
- Inflammation, 69, 70, 112, 136, 138, 140, 142, 143, 185–189, 193, 194, 203, 223, 225, 250
- ING2, 49, 244
- Inhibitor of growth protein 2, *see* ING2
- Inner and outer hair cells, 233
- Inositide 5-phosphatase, 216–219
- Inositol 1,3,4,5-tetrakisphosphate, 5, 97, 217–219, 231, 236, 239, 240, 283
- Inositol 1,4,5-trisphosphate, 62, 63, 67, 68, 217, 218, 231, 236, 239
- Inositol-phosphoceramides, 17, 19
- Inositol polyphosphate 5-phosphatase, 216, 217, 241, 252
- Inp51, 252
- Inp52, 218, 252
- Inp53, 252
- INPP4A*, 245–248, 257
- INPP4B*, 215, 245–248, 257
- INPP5A*, 217, 220, 239, 256
- INPP5B*, 220, 236–238, 240, 256
- INPP5E*, 220, 224, 225, 234–236, 256
- INPP5F*, 220, 236, 251, 252, 256, 257
- INPP5J*, 241, 242, 256
- INPP5K*, 257
- INPL-1*, 220, 227, 228, 231, 256
- Ins(1,3,4) P_3 , 218, 239, 246
- Ins(1,3,4,5) P_4 , *see* Inositol 1,3,4,5-tetrakisphosphate
- Ins(1,3,4,5) P_4 receptor, 217–219, 231, 240, 283
- Ins(1,4,5) P_3 , *see* Inositol 1,4,5-trisphosphate
- Insulin granules, 129
- Insulin mediated endocytosis, 196
- Insulin resistance, 150, 196, 228–230, 255, 295
- Insulin responsive cells, 100
- Insulinaemia, 229
- Insulin-like growth factor, 230
- Integrin-linked kinase (ILK), 130
- Intersectin 1, 231, 232
- Invadopodia, 36
- Invasion plasmid gene D (IpgD), 244
- Ion selectivity, 12, 232, 233, 306, 316
- IP₃ receptor, 49
- IP₃ receptor mobility, 49
- IpgD, 244, 246
- Iressa, *see* Gefitinib
- I κ B kinase (I κ BK), 134
- J**
- Joubert syndrome, 235
- Jun N-terminal kinase (JNK), 302
- K**
- Keratinocytes, 70, 231
- Kif13b, 316
- Knock-in mice, 101, 187, 190, 193
- Knock-out mouse, 71, 140, 196, 201, 218, 223, 232
- L**
- L6 myotubes, 242
- LAB/Lat2, 126, 140
- Lamellipodia, 33, 35, 229, 234, 240, 251
- Lamin B, 45
- lamp-1, 13
- LARG, 77, 78
- LAT, 75, 126, 140, 223
- Leishmania major*, 190
- Leptin receptor, 230
- Leucine zipper, 253
- Leukotriene B₄, 187
- Lhermitte-Duclos disease, 283, 289, 301
- Linker for activation of T cells (LAT), 75, 126, 140, 223
- Lipid signaling pathway, 101
- Lipid transfer activity, 17
- Lissencephaly, 242
- LL5 β , 227
- Long term potentiation (LTP), 250
- Loss of heterozygosity (LOH), 101, 102, 241, 243, 248
- Low-density lipoprotein, 138, 139
- Lowe oculocerebrorenal (OCRL) syndrome, *see* Lowe syndrome
- Lowe protein, 236; *see also* OCRL protein
- Lowe syndrome, 220, 236–240, 256; *see also* OCRL protein
- LPS, 69, 126, 127, 141, 191, 194
- L-selectin, *see* CD62L
- Lung adenocarcinoma, 243, 292
- LY294002, 9, 18, 98, 116, 117, 149, 188–190, 193
- Lymph node-homing receptor, 191
- Lymphocytes, *see* B lymphocytes and T lymphocytes
- Lyn, 75, 188, 221, 222
- Lysophosphatidic acid, 77, 78, 127, 129

M

M1-mtm-1, 307
 M1-muscarinic receptor, 73
 Macrocephaly, 289, 293
 Macrophages, 101, 136, 138, 139, 142, 185, 188, 221–226, 234
 Mal (MyD88-adaptor-like), 126
 Mannose-6-phosphate receptor (M6PR), 238
 Mast cells, 16, 138, 140–142, 188, 193, 221, 222, 225, 226
 Mastoparan, 7
 MDCK cells, 15, 16
 Megalin, 238, 239
 MEL cells, 48
 Membrane ruffles, 33, 35, 68, 238, 312
 Memory formation, 230
 Mental retardation, 235, 236, 240, 242
 Mesenchymal migration, 287, 294
 Metastatic adenocarcinoma, 235
 Methacoline, 193
 Mg²⁺-dependent phosphoesterase, 217
 Microspikes, 33
 Microvilli, 33
 Miller-Dieker syndrome (MDS), 242
 MIP, 307, 308
 Mitogen-activated protein kinase (MAPK), 17, 129, 147, 148, 151, 203, 222, 253
 Mitogen-activated protein kinase-activated kinase 2 (MAPKAP-2), 130
 MORM (mental retardation, obesity, congenital retinal dystrophy and micropenis), 235
 Motile actin comets, 33
 Mouse erythroleukemia (MEL), 45
 Mozart, 233
 mRNA export, 47
 Mss4p, 27, 29, 31, 46
 mtmr-9, 307, 314, 315
 mTOR (mammalian target of rapamycin), 103, 104, 116–119, 130, 131, 144, 148–151, 301
 mTORC1 (mTOR complex 1), 119–121
 mTORC2 (mTOR complex 2), 100, 119, 249
 Multiple myeloma, 120, 243
 Multivesicular bodies, 9
 Murine erythroleukemia (MEL) cells, 45, 48
 MVP (major vault protein), 288
 myc translocation, 300
 Myeloproliferative disease, 74, 222
 Myocardial infarction, 138, 140, 199, 203
 Myosin 1E, 231
 Myosin light chain kinase, 37
 Myotonic dystrophies, 316
 Myotubular myopathy, 112, 308, 312, 315

Myotubularin, 112, 249, 282, 283, 306, 307, 310–318

N

NADPH oxidase, 128, 135
 NCA (Na⁺/Ca²⁺ antiporter), 232, 233
 NCS-1, 8, 15
 Nedd4-1, 286
 Nephrin, 228
 Neuroexcitatory cell death, 247
 Neurofibrillary tangles, 70
 Neuronal cell migration, 242
 Neutrophils, 37, 73, 97–99, 128, 137, 138, 142, 185, 187, 192–194, 299, 305
N-formylmethionyl-leucyl-phenylalanine (fMLP), 97, 98, 187, 188
 NGF (nerve growth factor), 238
 NGF-differentiated PC12 cells, 241
 NK cells, 222
nla (nebula), 233
 NLS (nuclear localization signal), 46, 288
N-methyl-D-aspartate (NMDA) receptor
 Non-Hodgkin's lymphoma, 118–121, 235
 Non-kinase scaffolding function, 101
 Non-steroidal anti-inflammatory drugs (NSAIDs), 143
 NPXY motif, 221, 227
 NS5A, 14
 NTAL, 126, 140
 Nuclear envelope, 44, 45, 80
 Nuclear phosphoinositide cycle, 104
 Nuclear speckles, 45, 47, 48
 NVP-BEZ235, 103
 N-WASP, 35

O

OCRL gene, 217, 237, 238, 256
 OCRL protein, 220, 227, 236–240
 μ-Opioid receptor, 74
 OSBP1, 17
 Osteoclast activation, 226
 Ovalbumin (OVA), 141, 189, 193, 194
 Oxysterol-binding protein (OSBP), 7, 8, 13, 17

P

p50, 197
 p53, 49, 145, 244, 289, 299–301, 303
 p55, 197
 p70^{S6K}, 131, 147, 148, 199, 229, 242
 p85, 97, 98, 123, 145, 149, 184, 193, 197, 198, 246
 p110, 91, 101, 102, 104, 116
 p115RhoGEF, 77, 78
 p130Cas, 227

- Palmitoylation, 5, 6
 Pancreatic β -cells, 16, 129, 194, 195, 294
 Pancreatitis, 143
 Parkin, 302, 303
 Parkinson disease, 302, 303
 PCAF (p300/CBP-associated factor), 285
 PDGF (platelet-derived growth factor), 7, 10, 11, 35, 97–99, 116, 129, 236
 PDK-1 (phosphoinositide-dependent kinase-1), 100, 103, 126
 PDZ domain, 80, 249
Penicillium funiculosum, 98
 PEPCCK (phosphoenolpyruvate carboxykinase), 230
 Perinatal lethality, 101, 197
 Pertussis toxin, 127
 PEST sequence, 286
 Peutz-Jeghers syndrome, 147
 PH, *see* Pleckstrin homology
 Phagocytosis, 224, 225, 234, 305
 Pharbin, 234
 PH-GRAM, 307, 310
 5-phosphatase, 11, 217–219, 222, 223, 225–228, 231–243
 43 kDa 5-phosphatase, 217, 239
 75 kDa 5-phosphatase, 218, 240
 Phosphatidylinositol 3,5-bisphosphate [PtdIns(3,5)P₂], 217, 218, 234, 254, 282, 283, 306, 310, 313
 Phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P₂], 10, 12, 67, 68, 81, 95, 117, 123, 218, 232, 236, 282, 284
 Phosphatidylinositol kinase activity, 96
 Phosphatidylserine (PtdSer), 69
 Phosphodiesterase (PDE), 63, 101, 140, 201, 202
 Phosphoinositide phosphatase, 102, 131, 216, 222, 248–251
 Phospholamban, 201
 Phospholipase C (PLC), 26, 33, 62
 Phospholipase D (PLD), 138
 Phospholipid binding pocket, 30
Phox2a, 229
 PI3K/Akt signaling, 228, 230, 241, 242, 251, 284, 301
 PI 3-K-C2, 98
 PI 3-K effectors, 100, 102, 104
 PI3K complex I, 130
 PI3K complex II, 130
 PI4KII, 2
 PI4KIII, 2, 116, 117
 PIAS1, 221
 PICT-1, 286
 PIK domain, 202, 203
 Pik1, 4, 8, 9, 15
 Pik1p, 8, 15
PIK3CA, 102, 103, 145, 146, 184, 226
PIK3CB, 102
PIK3R1, 101, 102, 146, 184
PIK3R2, 184
PIK3R3, 184
 PIK93, 9, 12
 PIKfyve kinase, 282
 PINK1 (PTEN-induced putative kinase 1), 302, 303
 PIP₂, *see* Phosphatidylinositol 4,5-bisphosphate
 PIP₃, 26, 49, 187, 188, 195–199, 201, 202
 PIPKI, 27, 29–31, 37, 46
 PIPKII, 27, 29–31, 48
 PIX, 136
 PKA (protein kinase A), 27, 28, 31, 99, 201, 202, 249
 PKC (protein kinase C), 8, 11, 31, 45, 99, 196
 Platelet-activating factor (PAF), 189
 PLC γ 1, 221
 Pleckstrin-homology (PH), 99, 126, 135, 249, 282
 PML (promyelocytic leukemia protein), 288
 Podosomes, 36, 226
 Polycystic kidneys, 235, 296
 Polydactyly, 235
 Polymorphism, 129, 228
 Polyoma tumor DNA virus, 96
 Presynaptic nerve terminals, 231
 P-REX1 (PtdIns(3,4,5)P₃-dependent Rac exchanger), 103, 249–251
 P-REX2a, 249–251
 P-REX2b, 249
 Pro-apoptotic, 100, 302
 Profilin, 26, 33, 36, 68
 Progesterone receptor (PR), 248
 Proline-rich inositol polyphosphate 5-phosphatase, 241
 Proline-rich domains, 218, 227, 231
 Prostate cancer, 145, 150, 185, 248, 251, 288, 296, 297, 300
 Protein kinase D (PKD), 8, 17, 31
 Protein phosphatase, 131, 283, 286–288, 310
 Proteinuria, 236, 238, 239
 Proteus, 283
 Proteus-like syndrome, 283
 PTB domains, 221
 PtdIns3P, 96, 97, 99, 103, 112, 116, 117, 129
 PtdIns4P, 96, 116, 117

- PtdIns(3,4,5) P_3 , 63, 75, 117, 126, 135, 217, 218, 223–225, 227, 231, 236, 242, 283, 302, 310
- PtdIns(3,4,5) P_3 phosphatase, 101, 102
- PtdIns(4,5) P_2 , 10, 11, 67, 81, 117, 123, 217, 218, 231, 236, 240, 284, 310
- PTEN (phosphatase and tensin homolog deleted on chromosome 10), 102
- PTEN hamartoma tumor syndromes (PHTS), 301
- Punctate opacities in the lens, 236
- Purkinje cell, 13, 18, 247, 250
- PX domain, 62, 103, 135
- PxxP motifs, 221
- Q**
- Quercetin, 149
- R**
- R3-mtm-3, 307
- R5-mtm-5, 307
- R6-mtm-6, 307
- Rab1, 237, 238, 240
- Rab2, 240
- Rab5, 128, 130, 237, 238, 240, 247, 311
- Rab6, 237, 238, 240
- Rab9, 240
- Rab11, 8, 9, 37
- Rac, 8, 11, 73, 76, 99, 135, 225, 237, 238, 240, 249, 251
- Rac1, 35, 82, 234, 238, 239, 250, 251, 287
- Raf, 99, 151
- RalA, 69
- RalGDS, 99
- RAN (Ras-related nuclear protein), 288
- RANTES, 187
- Rap1, 77, 78
- Rapalogue, 311
- Raptor, 131, 146
- Ras, 63, 77, 78, 84, 99, 127, 128, 144, 145, 149, 151, 301
- Reactive oxygen species (ROS), 185, 188, 189, 225, 250, 301, 302, 305
- Readily-releasable pool, 37
- Respiratory burst, 101, 188, 189
- Retinal degradation, 235
- Retinoblastoma protein RB (pRB), 48
- Retrograde trafficking, 238, 240, 253
- Rheumatoid arthritis (RA), 141
- Rho superfamily, 103
- Rhodopsin, 71
- Rictor, 131, 146
- RID (Rac induced recruitment domain), 307
- RNA interference, 286
- RNA polymerase II, 47, 70
- ROCK, 37, 38
- ROS, *see* Reactive oxygen species
- RTK (receptor tyrosine kinase), 74, 76, 96, 98, 249
- Rubicon, 130
- Ryanodine receptor, 201, 315
- S**
- S phase, 70, 98, 104
- S6K1 (p70 ribosomal protein S6 kinase-1), 98, 104
- Sac domain, 218, 231, 251–253
- Sac domain-containing inositol phosphatases (SCIPs), 251, 252
- Sac domain phosphoinositide phosphatase, 251
- Sac1, 12, 17, 252, 253, 283
- Sac1 phosphatase, 18; *see also* Sac domain
- SAC2/INPP5F, 251
- Sac3, 254, 255
- SAC3/FIG4, 251, 254
- Salmonella*, 246
- Salmonella*-containing vacuole (SCV), 246
- SAM domain, 218, 227
- Sarcopenia, 316
- Schizophrenia, 73, 233
- Schizosaccharomyces pombe*, 67
- Schwann cells, 313, 316
- Ses1/2, 237, 238
- Sec3, 37
- Sec8, 316
- Second messenger, 12, 44, 45, 49, 62, 69, 97, 201, 217, 239, 282
- Sertoli cell, 241, 313
- SGK3 (serum and glucocorticoid-regulated kinase-3), 103
- SH2 (Src homology 2), 98
- SH3 domain, 74, 75, 83
- SH3-containing protein, 221
- Shc, 221, 227, 286
- Shigella flexneri*, 244
- SHIP (SH2-domain inositol phosphatase), 131, 137
- SHIP1 α , 219, 220
- SHIP1 δ , 219, 220
- Ship2, 228–230
- SID (set interacting domain), 307, 310, 314
- SigD/SopB, 246
- Single nucleotide polymorphisms (SNPs), 228, 316
- SKICH (SKIP carboxyl homology domains), 218, 241, 242

- SKIP (skeletal muscle and kidney inositol phosphatase), 236, 242, 243
- SLP-76, 75
- Smoothened, 17, 18
- SopB, 246
- Speckle targeted PIPKIalpha regulated-poly(A) polymerase (Star-PAP), 46
- Sperm function, 241
- Spermatids, 79, 241
- Sphingomyelin, 12, 16
- Sphingosine-1-phosphate receptor, 127
- Splenomegaly, 222, 297
- Squamous cell carcinomas (SCC), 231, 239
- Src, 26, 36, 43, 75, 96, 97, 221, 246, 286
- Staurosporine, 8, 149, 302
- Steatohepatitis, 289
- Sterile alpha motif (SAM), 218, 227
- Stomach cancer, 235
- Stress responses, 116
- Stt4p, 11
- Superoxide formation, 250
- Suppressor of morphogenesis in genitalia-1 (SMG-1), 116
- Swiss 3T3 cells, 45
- Syk, 75, 126, 140, 188
- Synaptic plasticity, 230, 232
- Synaptic vesicles, 13, 16, 217, 232, 233
- Synaptojanin 1, 218, 231–233, 252
- Synaptojanin 2, 231, 233, 234
- Synaptotagmin, 37
- Syndapin, 231
- SYNJ1*, 231, 233
- SYNJ2*, 231, 233
- Syntaxin 8, 13
- Systemic lupus erythematosus (SLE), 142, 143, 193
- T**
- T cell receptor interacting molecule (TRIM), 126
- T loop kinase, 100
- T lymphocytes, 136, 143, 189–191, 193, 222
- Talin, 32, 36, 38
- Tarceva, 151
- Telomere, 297
- Temsirolimus, 121, 148
- TG100-115, 118, 140, 141, 194
- Thr308, 100, 130
- Thrombin, 78, 127, 226
- Thrombin receptor, 77
- Thymocytes, 190
- TIRF (total internal reflection fluorescence) microscopy, 227
- TMEM55A, 244, 245, 257
- TMEM55B, 244, 245, 257
- Toll—IL-1 receptor domain-containing adaptor protein (TIRAP), 126
- Toll-like receptor (TLR), 126, 138
- TORC1, 103, 131, 147, 148, 150
- TORC2, 131, 146, 148
- Transcription, 47–49, 131, 134, 248, 250, 284
- Transferrin receptor, 238
- Transformation/transcription domain-associated protein (TRRAP), 116
- Transforming retroviral oncogene, 99
- Trans-membrane phosphatase with tensin homology (TPTE), 283
- Triose phosphate isomerase (TIM) barrel, 63, 65, 73, 74, 82, 83
- TrkA (tropomyosin receptor kinase A), 238
- Troponin I, 201
- TSC1, 131
- TSC2, 131, 147
- Tuberin, 131; *see also* TSC2
- Tumor suppressor, 48, 49, 70, 79, 102, 104, 145, 230, 248, 289, 305
- Type 2 diabetic patient, 197, 228
- Type III secretion machinery, 244
- Type IV 5-phosphatase, *see INPP5E*
- U**
- unc-80, 233
- Uncoating, 232
- 3'-untranslated region (UTR), 228
- UVRAG, 130
- V**
- Vac14, 254
- Vacuole, 26, 240, 246, 252
- v-Akt, 99
- Vascular endothelial growth factor (VEGF), 76, 144, 147
- Vasculogenesis, 76
- Vav, 136
- Villin, 35
- Vinculin, 36, 38
- Vinexin, 227
- Vps15p, 129
- Vps30p, 130
- Vps34, 116, 117, 129, 130, 282
- VSVG, 16, 17
- W**
- WASP, *see* Wiskott Aldrich Syndrome protein
- Weight gain, 229
- Winged helix/forkhead family, 69

Wingless, 10
Wiskott Aldrich Syndrome protein (WASP), 68
Wnt ligand, 10
Wnt signalling, 11
Wortmannin, 9, 11, 98, 101, 116, 117, 149,
150, 187–189, 193, 196, 197, 301
WW, 218, 227

X

Xenopus laevis, 75

X-linked centronuclear (myotubular) myopathy,
312
X-linked disorder, 236
X-linked myotubular myopathy, 112; *see also*
Myotubular myopathy

Y

YOTB, 135; *see also* FYVE domain

Z

ZAP-70, 75, 126